Brief: Rapt Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of Rpt904 (Jyb1904) in Chronic Spontaneous Urticaria
20/10/2025 13:17
Oct 20 (Reuters) - Rapt Therapeutics Inc RAPT.O: RAPT THERAPEUTICS AND SHANGHAI JEYOU PHARMACEUTICAL ANNOUNCE POSITIVE TOPLINE DATA FROM PHASE 2 TRIAL OF RPT904 (JYB1904) IN CHRONIC SPONTANEOUS URTICARIA RAPT THERAPEUTICS INC - RPT904 SHOWS COMPARABLE EFFICACY TO OMALIZUMAB RAPT THERAPEUTICS INC - RPT904 WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS RAPT THERAPEUTICS INC - JEYOU TO ADVANCE RPT904 TO PHASE 3 IN CHINA Source text: ID:nGNX1T5B6M Further company coverage: RAPT.O ((Reuters.Briefs@thomsonreuters.com;))